Issue 2/2015
Content (26 Articles)
Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis
Tomohiro Funakoshi, Maya Suzuki, Hyman B. Muss
Taking the next step: a systematic review and meta-analysis of physical activity and behavior change interventions in recent post-treatment breast cancer survivors
Shirley M. Bluethmann, Sally W. Vernon, Kelley Pettee Gabriel, Caitlin C. Murphy, L. Kay Bartholomew
The prognostic relevance of the mitotic activity index in axillary lymph node-negative breast cancer
Jan J. Jobsen, Job van der Palen, Mariël Brinkhuis, Johan W. R. Nortier, Henk Struikmans
Biological and clinical significance of PARP1 protein expression in breast cancer
Andrew R. Green, Daniela Caracappa, Ahmed A. Benhasouna, Alaa Alshareeda, Christopher C. Nolan, R. Douglas Macmillan, Srinivasan Madhusudan, Ian O. Ellis, Emad A. Rakha
INPP4B and RAD50 have an interactive effect on survival after breast cancer
Xiaofeng Dai, Rainer Fagerholm, Sofia Khan, Carl Blomqvist, Heli Nevanlinna
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
N. Elster, M. Cremona, C. Morgan, S. Toomey, A. Carr, A. O’Grady, B. T. Hennessy, A. J. Eustace
Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients
C. Benitez-Buelga, L. Sanchez-Barroso, M. Gallardo, María Apellániz-Ruiz, L. Inglada-Pérez, K. Yanowski, J. Carrillo, L. Garcia-Estevez, I. Calvo, R. Perona, M. Urioste, A. Osorio, M. A. Blasco, C. Rodriguez-Antona, J. Benitez
C-kit overexpression correlates with KIT gene copy numbers increases in phyllodes tumors of the breast
Junjun Liu, Xiaozhen Liu, Xiaolong Feng, Jian Liu, Shuhua Lv, Wei Zhang, Yun Niu
Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis
Yanchun Li, Jocelyn C. Reader, Xinrong Ma, Namita Kundu, Tyler Kochel, Amy M. Fulton
Long-term clinical outcomes in women with breast pain in the absence of additional clinical findings: mammography remains indicated
Mitra Noroozian, Lauren F. Stein, Kara Gaetke-Udager, Mark A. Helvie
Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy
Adam D. Pfefferle, Benjamin T. Spike, Geoff M. Wahl, Charles M. Perou
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial
Shuzhen Liu, Judy-Anne W. Chapman, Margot J. Burnell, Mark N. Levine, Kathleen I. Pritchard, Timothy J. Whelan, Hope S. Rugo, Kathy S. Albain, Edith A. Perez, Shakeel Virk, Garrett Barry, Dongxia Gao, Patti O’Brien, Lois E. Shepherd, Torsten O. Nielsen, Karen A. Gelmon
Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial
Claudia M. Witt, Oskar Außerer, Susanne Baier, Herbert Heidegger, Katja Icke, Oswald Mayr, Manfred Mitterer, Stephanie Roll, Gilbert Spizzo, Arthur Scherer, Christian Thuile, Anton Wieser, Lena Schützler
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
S. de Groot, L. G. M. Janssen, A. Charehbili, E. M. Dijkgraaf, V. T. H. B. M. Smit, L. W. Kessels, A. van Bochove, H. W. M. van Laarhoven, E. Meershoek-Klein Kranenbarg, A. E. van Leeuwen-Stok, C. J. H. van de Velde, H. Putter, J. W. R. Nortier, J. J. M. van der Hoeven, H. Pijl, J. R. Kroep
Increased pSmad2 expression and cytoplasmic predominant presence of TGF-βRII in breast cancer tissue are associated with poor prognosis: results from the Shanghai Breast Cancer Study
Qingchao Qiu, Yinghao Su, Ying Zheng, Hui Cai, Shenghui Wu, Wei Lu, Wei Zheng, Xiao Ou Shu, Qiuyin Cai
Premenopausal plasma 25-hydroxyvitamin D, mammographic density, and risk of breast cancer
Kimberly A. Bertrand, Bernard Rosner, A. Heather Eliassen, Susan E. Hankinson, Kathryn M. Rexrode, Walter Willett, Rulla M. Tamimi
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer
Anthony F. Yu, Nandini U. Yadav, Betty Y. Lung, Anne A. Eaton, Howard T. Thaler, Clifford A. Hudis, Chau T. Dang, Richard M. Steingart
Autoimmune diseases and breast cancer recurrence: a Danish nationwide cohort study
Lone Winther Lietzen, Deirdre Cronin-Fenton, Peer Christiansen, Henrik Toft Sørensen, Timothy L. Lash
History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response
Louise Huzell, Mia Persson, Maria Simonsson, Andrea Markkula, Christian Ingvar, Carsten Rose, Helena Jernström
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2
Celine M. Vachon, Daniel J. Schaid, James N. Ingle, D. Lawrence Wickerham, Michiaki Kubo, Taisei Mushiroda, Matthew P. Goetz, Erin E. Carlson, Soonmyung Paik, Norman Wolmark, Yusuke Nakamura, Liewei Wang, Richard Weinshilboum, Fergus J. Couch
Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis
María de Pedro, Sara Baeza, María-Teresa Escudero, Trinidad Dierssen-Sotos, Inés Gómez-Acebo, Marina Pollán, Javier Llorca
The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry
Ann J. Cloud, Ashley Thai, Yuyan Liao, Mary Beth Terry
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry
Tú Nguyen-Dumont, Fleur Hammet, Maryam Mahmoodi, Helen Tsimiklis, Zhi L. Teo, Roger Li, Bernard J. Pope, Mary Beth Terry, Saundra S. Buys, Mary Daly, John L. Hopper, Ingrid Winship, David E. Goldgar, Daniel J. Park, Melissa C. Southey
Invasive lobular carcinoma of the breast: local recurrence after breast-conserving therapy by subtype approximation and surgical margin
Lior Z. Braunstein, Jane E. Brock, Yu-Hui Chen, Linh Truong, Andrea L. Russo, Nils D. Arvold, Jay R. Harris
Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
Suleiman Massarweh, Edward Romond, Esther P. Black, Emily Van Meter, Brent Shelton, Vera Kadamyan-Melkumian, Mark Stevens, Richard Elledge
Erratum to: Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis
C. A. Drukker, S. G. Elias, M. V. Nijenhuis, J. Wesseling, H. Bartelink, P. Elkhuizen, B. Fowble, P. W. Whitworth, R. R. Patel, F. A. de Snoo, L. J. van’t Veer, P. D. Beitsch, E. J. Th. Rutgers